China VenturesChina Ventures 中华创投协会DEAL MARKETPLACE
Health & Bio · Beta

Advantage Data Vision

Virtual patient simulation to predict immunotherapy response.

BetaListings are in beta: details come from the parties and are not independently verified. Read the disclaimer.
RaisingHK$20m
StageSeed
RegionChina / Asia
ValuationTBC
TractionTwo AI modules (genomics and radiology) in evaluation at CUHK Shenzhen; US, China and Hong Kong patents; Google Cloud, Roche and HKSTP partnerships; investment agreement signed with an investor.
The business

What it does

Advantage Data Vision Limited builds an AI-driven virtual patient simulation system for liver cancer care. It fuses CT/MRI imaging, genomic profiles and clinical history into a digital twin of each patient to predict immunotherapy response, assess metastasis risk and support treatment selection, with a patient app and an encrypted Deep Feature QR code for cross-institution sharing. Two modules are in evaluation at CUHK Shenzhen; the company holds US, China and Hong Kong patents and has signed an investment agreement, with Google Cloud, Roche and HKSTP partnerships.

Members only

Login to see details

Sign in to see the summary, the evidence and use of funds for Advantage Data Vision. Membership is free.

We never publish contact details on the site. After approval the system will make an intelligent match.